Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies by Luigi Fattore et al.
Fattore et al. Journal of Translational Medicine 2013, 11:180
http://www.translational-medicine.com/content/11/1/180RESEARCH Open AccessActivation of an early feedback survival loop
involving phospho-ErbB3 is a general response of
melanoma cells to RAF/MEK inhibition and is
abrogated by anti-ErbB3 antibodies
Luigi Fattore1,2, Emanuele Marra3, Maria Elena Pisanu2,4, Alessia Noto1,2, Claudia de Vitis2,4, Francesca Belleudi1,5,
Luigi Aurisicchio3, Rita Mancini1,2, Maria Rosaria Torrisi1,5,6, Paolo Antonio Ascierto7 and Gennaro Ciliberto7*Abstract
Background: Treatment of advanced melanoma has been improved with the advent of the BRAF inhibitors.
However, a limitation to such treatment is the occurrence of resistance. Several mechanisms have been identified
to be responsible for the development of resistance, either MEK-dependent or MEK-independent. In order to
overcome resistance due to reactivation of MEK signaling, MEK inhibitors are being clinically developed with
promising results. However, also in this case resistance inevitably occurs. It has been recently reported that ErbB3, a
member of the EGFR receptor family, may be involved in the establishment of drug resistance.
Methods: Three melanoma cell lines were tested: LOX IMVI (BRAF V600E), MST-L (BRAF V600R) and WM266 (BRAF
V600D). Phosphorylation of Receptor Tyrosine Kinases (RTKs) was assessed by an RTK array. Western blot analysis was
performed on total protein extracts using anti-ErbB3, anti-AKT and anti-ERK 1/2 antibodies. The expression of
neuregulin after vemurafenib treatment was assessed by Real Time PCR and Western blotting. The growth inhibitory
effects of vemurafenib, GSK1120212b and/or anti-ErbB3 mAbs were evaluated by in vitro colony formation assays.
Results: In the present study we demonstrate that ErbB3 is the main RTK undergoing rapidly hyperphosphorylation
upon either treatment with a BRAF inhibitor or with a MEK inhibitor in a panel of melanoma cell lines harboring a
variety of V600BRAF mutations and that this results in a strong activation of phospho-AKT. Importantly, ErbB3 activation
is fully abrogated by the simultaneous use of anti-ErbB3 monoclonal antibodies, which are also shown to potently
synergize with BRAF inhibitors in the inactivation of both AKT and ERK pathways and in the inhibition of melanoma cell
growth. We show that upregulation of phospho-ErbB3 is due to an autocrine loop involving increased transcription
and production of neuregulin by melanoma cells.
Conclusions: On the basis of these results, we propose that initial co-treatment with BRAF and/or MEK inhibitors and
anti-ErbB3 antibodies should be pursued as a strategy to reduce the ErbB3-dependent feedback survival mechanism
and enhance duration of clinical response.
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Malignant melanoma is the deadliest form of skin cancer.
Over the last 60 years there has been an approximate 700%
increase in the incidence of melanoma world-wide and
mortality has also increased by 165% [1]. Disease-specific
survival curves in all stages of melanoma have a negative
slope and overall prognosis is poor with less that 5% of
stage 4 patients surviving 5 years from the manifestation of
metastatic disease [1]. Before 2011 only three drugs were
FDA-approved for metastatic melanoma, fotemustine,
dacarbazine and high-dose IL2, all of them giving rise to
modest response rates (6 to 15%) with median progression
free survival (PFS) of 1.7 months, only 25.5% of patients
still alive at 1 year and rare long-term regressions [2]. In re-
cent years however, the scenario has completely changed
thanks to the development of innovative systemic therap-
ies. In first instance immunotherapy with ipilumumab has
demonstrated improved survival in patients with advanced
melanoma in Phase III randomized trials [3]. At the same
time novel agents directed to target cell autonomous
disregulated pathways have shown remarkable clinical ef-
fects. The first one is vemurafenib, a selective inhibitor of
BRAF-activating mutations which are found in more than
50% of melanomas and which cause constitutive activation
of the MAPK/ERK pathway driving uncontrolled melan-
oma growth. In a first Phase I trial vemurafenib (previ-
ously called PLX4032) achieved an objective response rate
in excess of 50-60% in advanced disease [4]. Subsequently
a phase III study comparing vemurafenib to dacarbazine
showed a significant increase in survival for patients re-
ceiving vemurafenib [5]. Other more potent BRAF inhibi-
tors are in advanced clinical development, having achieved
promising results in early trials [6]. It is important to point
out that BRAF inhibitors are active only in tumors where
V600 BRAF mutations result in constitutively active mono-
mers, whereas the same inhibitors give rise to paradoxical
tumor promoting effects in RAS mutated melanomas be-
cause of their ability to induce allosteric activation through
homo- or hetero-dimerization of wild type RAF isoforms
[7,8]. Hence, the current strategy to tackle NRAS mutated
melanomas involves the use of inhibitors of more down-
stream kinases in the RAS-RAF-MAPK pathway, in particu-
lar MEK [9]. In line with this, very recently MEK inhibitors
have shown clinical activity as single agents in patients bear-
ing mutated NRAS [10].
Although BRAF inhibitors (BRAFi) induce unprecedented
objective responses virtually all responders suffer from dis-
ease progression due to the development of de novo drug
resistance [11,12]. Thus, in order to significantly improve
melanoma survivability it is necessary to develop new ap-
proaches to overcome or, better, avoid the development of
resistance to BRAFi. Recent investigations suggest that there
are multiple mechanisms responsible for the establishment
of resistance to BRAFi, which can be grouped into twomajor modes MEK-dependent and MEK-independent
[13,14]. In the first and more frequent case, reactivation
of the MAPK pathway occurs, for example through the
acquisition of novel N-RAS mutations or V600E BRAF
truncations resulting in RAS-independent RAF dimerization
with other members of the same family. In the second
case cancer growth depends upon activation of signal-
ing pathways redundant to MAPK, for example via
overexpression of RTKs, such as PDGFR or IGF1R,
which promote activation of the PI3K-AKT pathway.
These mechanisms have been observed both in melan-
oma cell cultures exposed in vitro to continuous selec-
tion with BRAF inhibitors, and in post-relapse human
melanoma tumor samples [14,15]. Importantly, second-
ary mutations in V600E BRAF have not been identified in
drug-resistant tumors, thus arguing that the strategy to
overcome BRAFi resistance in melanoma has to rely on
the development of combinatorial approaches.
The evidence that resistance to BRAFi frequently de-
pends upon reactivation of the MAPK pathway has led to
the development of novel strategies directed to simultan-
eously co-target BRAF and MEK in the attempt to mitigate
the emergence of resistance [15]. Indeed, MEK inhibitors
have been shown to increase progression free survival
when delivered in combination with a BRAF inhibitor as
compared to BRAF inhibitor monotherapy [16]. However,
even if combinatorial treatment with BRAFi and MEKi
gives rise to increase in time to progression as compared
to BRAFi monotherapy, this approach is unable to com-
pletely eradicate disease, most likely because of MAPK-
independent adaptive changes taking place in melanoma
cells upon exposure to inhibitors of this pathway. There-
fore additional approaches are under study which include
for example combination treatments with MEK and IGF1R/
PI3K inhibitors [15].
The EGFR family of receptor tyrosine kinases consists of
four closely related family members: EGFR (Her1), ErbB2
(HER2), ErbB3 (Her3), and ErbB4 (Her4) [17]. These recep-
tors are important regulators of normal growth and cell dif-
ferentiation. Their gene amplification, overexpression or
mutation is associated with tumor development and poor
clinical prognosis in most of the human cancers [18]. EGFR
and HER2, have been among the most extensively studied
for the therapy of cancer over the past twenty years and a
wealth of drugs directed against them have been either
already approved or are in advanced clinical development
[18]. Although ErbB3 has been disregarded for several years
as a target for cancer therapies recent meta-analysis of
ErbB3 expression in several solid tumor demonstrated that
increased levels of receptor are constantly associated with
worse survival [19]. Indeed, during the last years several evi-
dences have been accumulated pointing to a key role of this
receptor in tumorigenesis and cancer progression both as a
node in ligand-induced signalling by members of the EGFR
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apies in lung and breast cancer [21-23], which fueled efforts
towards the development of ErbB3 inhibitors [24]. We have
recently shown that melanoma cells often express ErbB3 in
concert with other ErbBs and that neuregulin, acting
through ErbB3, activates the PI3K/AKT pathway, thus lead-
ing to increased cell survival, proliferation and migration
[25]. Furthermore, we have generated a set of three anti-
human ErbB3 monoclonal antibodies (mAbs) in our labora-
tory A2, A3 and A4 [26]. These antibodies have been
characterized biochemically and functionally [25,26]. These
studies led to conclude that, at least in melanoma cell cul-
tures, A3 and A4, but not A2 are able to strongly inhibit
ligand-induced signalling, proliferation and migration. In
the attempt to understand their mechanism of action, we
demonstrated through a series of combined approaches
that antibody efficacy correlated with the ability to induce
receptor internalization, degradation and inhibition of re-
ceptor recycling to the cell surface [25].
In the present work we show that ErbB3 is central to a
feedback survival loop activated in melanoma cells upon
exposure to BRAF and/or MEK inhibitors, that this activa-
tion is dependent upon increased production and release
of neuregulin by melanoma cells and, most importantly,
that antibodies against ErbB3 capable to induce receptor
degradation, abolish this loop and strongly potentiate the
antitumor efficacy of BRAF and or MEK inhibitors when
given in combination.
Methods
Cell lines and treatments
Human melanoma cell lines LOX IMVI, MST-L and
WM266 were cultured in RPMI supplemented with 10%
FBS. To evaluate ErbB3, AKT and ERK 1/2 signaling and
neuregulin expression melanoma cells were serum starved
for 24 h and treated with vemurafenib and/or GSK1120212
at different doses and times and incubated or not with
20 μg/ml of anti-ErbB3 mAbs A4, A3 or A2 . To determine
effects on proliferation melanoma cell lines, seeded at
1*105/ well, were treated with increasing concentrations
(from 0,002 to 1 μM) of vemurafenib and/or GSK1120212
alone or in combination with anti-ErbB3 mAbs for 10 days.
To evaluate neuregulin (HRG) release LOX IMVI cells
were treated for 24 h with vemurafenib and then the condi-
tioned medium of BRAFi treated cells (pre-incubated or
not with the anti-HRG antibody) was used to stimulate
starved LOX IMVI cells for 1 h.
Antibodies and reagents
Antibodies against AKT, ERK 1/2, phospho-ErbB3,
phospho-AKT and phospho-ERK 1/2 were purchased
from Cell Signaling Technology. Anti-ErbB3, anti-HRG
and anti-GAPDH were obtained from Santa Cruz Bio-
technology. Anti-rabbit and anti-mouse were purchasedfrom AbCam. The anti-HRG (blocking peptide) was
purchased from Thermo Scientific. Anti ErbB3 anti-
bodies A2, A3 and A4 have been described previously
by our laboratory [25,26]. The three anti-ErbB3 anti-
bodies are all of the IgG1 isotype (EM unpublished
observation). Vemurafenib and GSK1120212 were
obtained from Selleck Chemicals. TaqMan probes for
HRG and housekeeping gene 18S were purchased from
Applied Biosystems.Phospho-RTK array
A human phospho-RTK array (R&D Systems) was used to
detect simultaneously the phosphorylation status of RTKs
(n = 49) in melanoma cells. Membranes were incubated
with cell lysates (100 μg) overnight according to the
manufacturer' s protocol. After washing, the membranes
were incubated with a phosphotyrosine antibody conju-
gated to horseradish peroxidase to allow the detection of
captured RTKs that are phosphorylated. Array data on im-
ages were analyzed using Photoshop Quantity One Pro-
gram (Bio-Rad LaboratoriesGmbH). Duplicate dots in
each corner are positive controls.Western blot analysis
Melanoma cells were lysed with RIPA buffer; 50 μg of total
protein were resolved under reducing conditions by 8%
SDS-PAGE and transferred to reinforced nitrocellulose
(BA-S 83, Schleider and Schuell, Keene, NH, USA). The
membranes were blocked with 5% non fat dry milk in PBS
0.1% Tween 20, and incubated with the different primary
antibodies. The membranes were rehydrated and probed
again with anti-GAPDH, to estimate the protein equal load-
ing. Densitometric analysis was performed using Quantity
One Program (Bio-Rad Laboratories GmbH) and results
were expressed as mean values from three independent
experiments.RNA extraction and real-time PCR analysis
RNA was extracted using TRIzol method (Invitrogen)
according to manufacturer’s instruction and eluted with
0,1% diethylpyrocarbonate (DEPC)- treated water. Total
RNA was quantitated by spectrophotometry. Real Time-
PCR was assayed by TaqManW Gene Expression Assays
(Applied Biosystems, Foster City, CA). To normalize the
amount of source RNA, 18S transcript from the same
sample was measured and used as internal reference.
Each targeted transcript was validated using the com-
parative Ct method for relative quantification (ΔΔCt)
reference to the amount of a common reference gene
(18S). The fold difference was calculated using the com-
parative ΔΔCt and results were reported as mean values
from three independent experiments.





























































 1    2    3    4
pErbBs
a b
  0 0.3       0.1      0.03      0.3      0.1     0.03 
MST-L
                 6h                                   24h
      1      1             1  1.1          4.3         3.4         1.9
      1    0.1          0.1 0.5          0.4          0.3         0.6





    0 0.3      0.1      0.03       0.3      0.1     0.03 
                 6h                                   24h
       1       1           0.9  1.1           15          7.8         6.5
        1       1             1   0.8         12.1       12.7        7.2











  vem (μM)
c d
PDGFR β PDGFR βIGF-1 R IGF-1 R 
Figure 1 (See legend on next page.)
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Figure 1 Vemurafenib treatment induces selective ErbB3 phosporylation in melanoma cells. Simultaneous detection of the
phosphorylation status of RTKs (n = 49) using a human phospho-RTK array in LOX IMVI (a) and MST-L (b) melanoma cells treated or not for 24 h
with 0.3 μM vemurafenib. Membranes were incubated with cell lysates (100 μg) overnight according to the manufacturer' s protocol. The array
detects the tyrosine-phosphorylated RTKs simultaneously in duplicate (1, pErbB1; 2, pErbB2; 3, pErbB3; 4, pErbB4). Duplicate dots in each corner
are positive controls. Array data on images were analyzed using Photoshop Quantity One Program (Bio-Rad LaboratoriesGmbH). The
phosphorylation of ErbB3 is strongly increased by vemurafenib treatment. LOX IMVI (c) and MST-L (d) cells were serum starved for 24 h, treated
or not with different doses of vemurafenib for 6 h or 24 h. Western blot analysis performed using the indicated antibodies shows that
vemurafenib induces a strong dose-dependent and time-dependent phosphorylation of ErbB3 and AKT. For densitometric analysis pErbB3/ErbB3,
pERK/ERK and pAKT/ATK values are expressed as fold change with respect to the control unstimulated cells to which value = 1 was assigned.
Results are reported as mean values ± standard deviation (SD) from three independent experiments.
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Cells viability was determined by crystal violet staining.
Briefly, the cells were stained for 20 min at room
temperature with staining solution (0,5% crystal violet
in 30% methanol), washed four times with water and
then dried. Cells were then dissolved in a Methanol/
SDS solution and the adsorbance (595 nm) was read
using a microplate ELISA reader.Statistical analysis
Quantitative analyses for curve fitting and for IC50 evalu-
ation, were performed by KaleidaGraph software. p-values
were calculated using Student’s t test and significance level
has been defined as p < 0,05.Results and discussion
ErbB3 is the only RTK rapidly phosphorylated upon
exposure of BRAF mutated melanoma cells to
vemurafenib
In order to identify the mechanism responsible for early
adaptive changes of melanoma cells to BRAF inhibition,
we postulated that receptor tyrosine kinases may be im-
portant sensors. Hence, we utilized an RTK array to detect
early changes in the phosphorylation level of approximately
fifty RTKs. LOX IMVI melanoma cells bearing the most
frequent oncogenic BRAF mutation V600E [27] were
treated for 24 h with 0.3 μM vemurafenib. Surprisingly we
found that, while the phosphorylation level of most re-
ceptors remained unchanged or was subjected to subtle
variations, the only receptor whose phosphorylation
was consistently upregulated 50–100 fold was ErbB3
(Figure 1a). These results were confirmed in two other
melanoma cell lines, MST-L [25] bearing a V600R mu-
tation (Figure 1b) and WM266 bearing a V600D [27]
mutation (Additional file 1: Figure S1a). Hence, ErbB3
is the major RTK undergoing hyperphosphorylation
upon BRAF inhibition in melanoma cells bearing dis-
tinct BRAF mutations as well as different ErbB receptor
compositions (Additional file 2: Table S1). This strongly
suggests that this is a general phenomenon taking place
in melanoma when BRAF is inhibited.Cell extracts of melanoma cell lines LOX IMVI and
MST-L exposed to vemurafenib at different doses and
times were prepared and subjected to western blotting.
The results (Figure 1c and d) show that ErbB3 under-
goes a strong dose- and time-dependent upregulation of
its phosphorylation in the absence of external addition
of neuregulin (HRG). Feedback activation of pErbB3
was accompanied by increased phosphorylation of AKT
(Figure 1c and d), which suggests the activation of a
pro-survival loop contributing to dampen the efficacy of
BRAF inhibitors. Importantly the same findings were
confirmed in WM266 (Additional file 1: Figure S1b). It
is important to point out that pErbB3 upregulation takes
place in the absence of increased levels of ErbB3 protein
(see WBs in Figure 1c and d and Additional file 1: Figure
S1b) and in the absence of increased levels of ErbB3 and
FOXD3 mRNA as indicated by gene expression profiling
of untreated vs vemurafenib treated melanoma cells (not
shown).
BRAF inhibitor-induced feedback survival loop is
abrogated by anti-Erbb3 antibodies
We therefore assessed the effect of the anti-ErbB3 anti-
body A4 generated in our lab and able to inhibit the
ligand-induced signaling and to potently induce receptor
internalization and degradation [25,26], on vemurafenib-
induced pErbB3 and pAKT levels and found that this
was able to completely abrogate receptor phosphoryl-
ation and AKT signaling in all cell lines tested (Figure 2a,
for LOX IMVI and Additional file 3: Figure S2a and c
for MST-L and WM266 respectively). Also, it is import-
ant to notice that the combined treatment led to a
stronger degree of pERK down regulation.
In order to assess whether inhibition of pErbB3 and
pAKT could result in potentiation of the growth inhibi-
tory effects of vemurafenib, in vitro colony formation
assays were carried out in the presence of growing con-
centrations of vemurafenib alone or in combination
with a fixed dose of A4. Remarkably, treatment with
anti-ErbB3 mAb strongly potentiated growth inhibition
by vemurafenib (Figure 2b and c for LOX IMVI and
Additional file 3: Figure S2b and d for MST-L and
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Figure 2 (See legend on next page.)
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Figure 2 Anti-ErbB3 mAbs differently counteract the increase of ErbB3-dependent AKT phosphorylation and potentiate growth
inhibition induced by vemurafenib. LOX IMVI melanoma cells serum starved and treated with vemurafenib (0.3 μM) for 24 h were incubated or
not with 20 μg/ml of anti-ErbB3 mAbs A4 (a), A3 or A2 (d). Western blot analysis shows that A4 and A3, but not A2 mAbs abrogate receptor
phosphorylation and ATK signaling. For densitometric analysis pErbB3/ErbB3, pERK/ERK and pAKT/ATK values are expressed as fold change with
respect to the control unstimulated cells to which value = 1 was assigned. Results are expressed as mean values from three independent
experiments. LOX IMVI cells were grown in the presence of different doses of vemurafenib alone or in combination with 20 μg/ml of A4 (b), A3
or A2 (e) mAbs for 10 days. Cells were then fixed and stained with crystal violet (c). Cells were then dissolved in a Methanol/SDS solution and
the adsorbance (595 nm) was read using a microplate ELISA reader (b, e). Quantitative analysis for curve fitting and for IC50 evaluation,
performed by KaleidaGraph software, shows that the treatment with A4 and A3 but not with A2 enhances the inhibitory effect of vemurafenib
on cell growth (IC50 vem = 155 nM; IC50 vem + A4 = 36 nM; IC50 vem + A3 = 62, IC50 vem + A2 = 146 nM). Results are reported as mean values ±
standard deviation (SD) from three independent experiments. p-values were calculated using Student’s t test and significance level has been
defined as p < 0,05. For IC50 vem + A4 and IC50 vem + A3 p < 0,001 vs IC50 vem; IC50 vem + A2 NS vs IC50 vem.
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specificity of this effect we tested in LOX IMVI cells
two other anti-ErbB3 mAbs from our collection, namely
A3 and A2 which were previously shown to be able to
inhibit or not ErbB3-dependent signaling respectively
[25]. As expected only A3 but not A2 was able to com-
pletely abrogate vemurafenib-induced ErbB3 phosphor-
ylation and AKT signaling (Figure 2d). Moreover in
in vitro colony formation assays only A3 but not A2
strongly potentiated growth inhibition by vemurafenib
(Figure 2e).
The ErbB3 feedback survival loop is activated also upon
MEK inhibition
The evidence that one of the most frequent mechanisms re-
sponsible for the development of stable resistance to BRAF
is reactivation of the MAPK/ERK pathway has driven the
clinical development of MEK inhibitors [14,16].
We have, therefore, investigated whether the ErbB3-
dependent feedback survival loop is activated also by
MEK inhibitors. To this purpose we treated LOX-IMVI
cells with GSK1120212b. As it is shown in Figure 3a and
Additional file 4: Figure S3, a strong induction of pErbB3,
with concomitant increase of pAKT was observed 24 h
after cell exposure to the MEK inhibitor. Also in this case
the feedback survival loop was fully abrogated by the
addition of the anti-ErbB3 mAb A4 (Figure 3a). In vitro
colony formation assays were run in the presence of grow-
ing concentrations of GSK1120212b alone or in combin-
ation with a fixed dose of A4. Also in this case, co-treatment
with anti-ErbB3 strongly potentiated growth inhibition by
the MEK inhibitor (Figure 3b). Our results clearly indicate
that targeting of the RAS-RAF-MAPK pathway at multiple
levels is unable to avoid bypass activation of the AKT-
dependent adaptive mechanism centered around ErbB3,
and that cell treatment with anti-ErbB3 has a dominant ef-
fect on both pAKTand pERK when combined with a BRAF
and MEK inhibition. Finally when cells were treated with
suboptimal doses of vemurafenib and GSK1120212b, the
addition of A4 was capable to provide a powerful synergis-
tic inhibition of cell growth (Figure 3c).The feedback survival loop is promoted by increased
autocrine production of neuregulin by melanoma cells
We were interested to better dissect the molecular
mechanism responsible for drug-dependent pErbB3
upregulation. Normally, ErbB3 is phosphorylated fol-
lowing ligand-dependent hetero-dimerization with
other HER-family receptor partners. Since BRAF or
MEK inhibitors induce pErbB3 in melanoma cells bear-
ing different HER-family receptor composition (see
Additional file 2: Table S1) we reasoned that a common
mechanism could be the increased production and re-
lease of neuregulin in the medium and activation of an
autocrine loop. Indeed, real time PCR analysis of LOX
IMVI cells treated at different times with vemurafenib
showed increased neuregulin mRNA levels 24 h after
treatment (Figure 4a). This was accompanied by increased
production of neuregulin as detected by western blotting
(Figure 4b). To confirm that the autocrine production of
neuregulin is responsible for the ErbB3-mediated survival
loop in response to BRAF inhibitor LOX IMVI cells were
treated with vemurafenib in presence or not of a neutraliz-
ing antibody against neuregulin (Figure 4c). Western blot
analysis clearly showed that the anti-HRG antibody
strongly inhibit both pErbB3 and consequently pAKT. To
further confirm this, the conditioned medium of BRAFi
treated melanoma cells was able to induce pErbB3 in
starved melanoma cells with a very rapid kinetic, after
1 hour exposure (Figure 4d). Finally in order to fully
prove that this mechanism is entirely dependent upon
increased production of the ligand, the conditioned
medium was pre-incubated with neutralizing antibodies
against neuregulin. As shown in Figure 4d, this treat-
ment fully abrogated pErbB3 induction by the condi-
tioned medium of drug-treated melanoma cells.
Conclusions
A current limitation of targeted therapies against meta-
static melanoma with BRAF or MEK inhibitors is the
development of resistance. Hence it is of utmost im-
portance to identify and tackle the underlying mecha-
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Figure 3 Anti-ErbB3 mAb A4 counteracts the increase of ErbB3-dependent AKT phosphorylation and potentiate growth inhibition
induced by GSK1120212b. (a) LOX IMVI melanoma cells were serum starved and treated with vemurafenib (0.3 μM), with GSK1120212b (GSK,
0.15 μM) or with their combination in presence or not of anti-ErbB3 mAb A4 (20 μg/ml) for 24 h. Western blot analysis shows that A4 mAb
abrogate ErbB3 phosphotylation as well as the strong increase of pAKT induced by both inhibitors. For densitometric analysis pErbB3/ErbB3,
pERK/ERK and pAKT/ATK values are expressed as fold change with respect to the control unstimulated cells to which value = 1 was assigned.
Results are expressed as mean values from three independent experiments. (b) Cells were grown in the presence of different doses of GSK
combinated or not with A4 mAb (20 μg/ml) for 10 day. Cells were then dissolved in a Methanol/SDS solution and the adsorbance (595 nm) was
read as above. Quantitative analysis for curve fitting and for IC50 evaluation, performed as above, shows that the treatment with A4 enhances the
inhibitory effect of GSK on cell growth (IC50 GSK = 115 nM; IC50 GSK + A4 = 19 nM). p-values were calculated and significance level has been
defined as above. For IC50 GSK + A4 p < 0,001 vs IC50 GSK. (c) Cells were treated with suboptimal doses of vemurafenib, GSK or their
combination in presence or not of A4 mAb (c). The in vitro colony formation assay shows that the addition of A4 significantly inhibits cells
growth. *p < 0,01 vs vem-treated or GSK-treated cells; ** p < 0,001 vs vem + GSK- treated cells; NS vs untreated cells.
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vemurafenib, which develops after prolonged exposure
to the drug in vitro or in vivo, is caused by mutually ex-
clusive mechanisms: either mutations in N-RAS or up
regulation of PDGFR/ IGF1R signaling. These changes
are presumably the resultant of a prolonged process
preceded by adaptive changes which allow cells to sur-
vive while long-term stable resistant are selected. In the
present work we have decided to focus our attention on
these early adaptive changes in order to identify the major
pathways involved. As first approach we carried out an
RTK array to identify receptor tyrosine kinases undergoingvariations in their phosphorylation after short-term expos-
ure to vemurafenib. Surprisingly, we found that in the
three melanoma cell lines tested, the only receptor which
underwent prominent hyperphosphorylation was ErbB3. It
has to be pointed out that in this early phase, at least in
the cell lines used in our study, both PDGFR and IGF1R
didn’t modify their level of phosphorylation, which leads
us to conclude that the involvement of these receptors
may occur only at a later time when long-term resistant
clones are selected [14,15].
Abel et al. have recently reported that melanoma cells
adapt to RAF/MEK inhibitors through a FOXD3-mediated
Fattore et al. Journal of Translational Medicine 2013, 11:180 Page 9 of 11
http://www.translational-medicine.com/content/11/1/180upregulation of ErbB3 transcription [28], which induced cell
sensitization to the biological effect of exogenously added
ErbB3 ligand neuregulin. A similar involvement of ErbB3
was also previously suggested by Lito et al. [7]. Our
biochemical findings are entirely novel and substantially dif-
fer from the previous ones. The major difference is that,
while Abel et al. attribute the involvement of ErbB3 to in-
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Figure 4 Vemurafenib treatment induces increased expression and re
serum starved for 24 h and treated or not with vemurafenib (0,3 μM) for 1,
probes (a) and Western blot analysis performed using anti-HRG antibody (b
increased at both mRNA and protein levels. For PCR and Western Blot anal
from three independent experiments. (c) Cells were treated with vemurafe
Anti-ErbB3 A2 mAb was used as negative control. The anti-HRG antibody, b
triggered by vemurafenib. (d) Cells treated for 1 h with the conditioned m
vemurafenib-stimulated LOX IMVI cells (vem CM) were pre-incubated or no
anti-HRG antibody, but not A2 mAb abrogates both ErbB3 and AKT phosph
ErbB3, pERK/ERK and pAKT/ATK values are expressed as fold change with r
assigned. Results are expressed as mean values from three independent exexposure to vemurafenib, which leads to a moderate 2-fold
increase in ErbB3 protein levels, we do not detect major
variations in total ErbB3 protein levels upon exposure to ei-
ther a BRAF or to a MEK inhibitor. In contrast we detect a
prominent (several-fold) spontaneous hyperphosphorylation
of the receptor consequent to the increased cell produc-
tion and release of neuregulin with consequent activa-
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lease of neuregulin (HRG) in LOX IMVI melanoma cells. Cells were
6 or 24 h. Real-time PCR analysis performed using specific TaqMan
) show that upon 24 h of vemurafenib treatment HRG expression is
yses results are reported as mean values ± standard deviation (SD)
nib in presence or not of a neutralizing anti-HRG antibody. The
ut not A2 mAb, strongly inhibits both ErbB3 and AKT phosphorylation
edium (CM) from untreated-LOX IMVI cells (untreated CM) or from
t with the anti-HRG antibody or with A2 mAb. The treatment with the
orylation induced by vem CM. For densitometric analysis pErbB3/
espect to the control unstimulated cells to which value = 1 was
periments.
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http://www.translational-medicine.com/content/11/1/180these significant discrepancies. However it is worth
pointing out that Abel et al. use melanoma cells stably
transfected with a plasmid encoding Foxd3, and which
therefore express supraphysiological amounts of this
transcription factor [28]. In contrast we never transfect
this factor and, therefore, we believe we work in more
physiological conditions.
In addition we show for the first time that neutralizing
antibodies against ErbB3 are capable to fully abrogate
this compensatory survival mechanism and to potently
synergize with BRAF and MEK inhibitors. Therefore,
we propose that initial co-treatment of melanoma pa-
tients bearing BRAF mutations with an anti-ErbB3 anti-
body could be a powerful strategy to enhance clinical
efficacy of BRAF and MEK inhibitors.
Additional files
Additional file 1: Figure S1. Vemurafenib treatment induces selective
ErbB3 phosphorylation in WM266 melanoma cells. (a) Simultaneous
detection of the phosphorylation status of RTKs (n = 49) using a human
phospho-RTK array in WM266 melanoma cells treated or not for 24 h
with 0.3 μM vemurafenib. Membranes were incubated with cell lysates
and array data were analyzed as reported in Figure 1. The
phosphorylation of ErbB3 is strongly increased by vemurafenib treatment.
(b) WM266 cells were serum starved for 24 h, treated or not with
different doses of vemurafenib for 6 h or 24 h. Western blot analysis
shows a strong dose-dependent and time-dependent phosphorylation of
ErbB3 and AKT induced by vemurafenib. For densitometric analysis
pErbB3/ErbB3, pERK/ERK and pAKT/ATK values are expressed as fold
change with respect to the control unstimulated cells to which value = 1
was assigned. Results are reported as mean values ± standard deviation
(SD) from three independent experiments.
Additional file 2: Table S1. Flow cytometry analysis of ErbBs
membrane expression in LOX IMVI, MST-L and WM266 melanoma cell
lines. The percentage of positive cells was determined by staining with
the indicated primary antibodies and with the isotype-matched
andibodies as negative control. LOX IMVI, MST-L and WM266 show
different ErbB receptor compositions.
Additional file 3: Figure S2. Anti-ErbB3 A4mAb counteracts the
increase of ErbB3-dependent AKT phosphorylation and potentiate growth
inhibition induced by vemurafenib in melanoma cells. MST-L (a) and
WM266 (c) cells serum starved and treated with vemurafenib (0.3 μM) for
24 h were incubated or not with A4 mAb (20 μg/ml). Western blot
analysis shows that A4 abrogate receptor phosphorylation and ATK
signaling. For densitometric analysis pErbB3/ErbB3, pERK/ERK and pAKT/
ATK values are expressed as fold change with respect to the control
unstimulated cells to which value = 1 was assigned. Results are expressed
as mean values from three independent experiments. MST-L (b) and
WM266 (d) cells were grown in the presence of different doses of
vemurafenib alone or in combination with a fixed dose (20 μg/ml) of A4.
Cells were then dissolved in a Methanol/SDS solution and the
adsorbance (595 nm) was read as reported in Figure 2. Quantitative
analysis for curve fitting and for IC50 evaluation, performed as reported
in Figure 2, shows that A4 enhances the inhibitory effect of vemurafenib
on both cell lines’ growth (for MST-L cells: IC50 vem = 264 nM, IC50 vem
+ A4 = 69 nM; for WM266 cells IC50 vem = 140 nM, IC50 vem + A4 = 51
nM). Results are reported as mean values± standard deviation (SD) from
three independent experiments. p-values were calculated and
significance level has been defined as reported in Figure 2. For MST-L
and WM266 cells IC50 vem + A4 p < 0,001 vs IC50 vem.
Additional file 4: Figure S3. GSK1120212b treatment induces selective
ErbB3-dependent AKT phosphorylation in LOX IMVI melanoma cells. Cells
were serum starved for 24 h, treated or not with different doses of GSKfor 6 h or 24 h. Western blot analysis performed using the indicated
antibodies shows that GSK induces a strong dose-dependent and time-
dependent phosphorylation of ErbB3 and AKT. For densitometric analysis
pErbB3/ErbB3, pERK/ERK and pAKT/ATK values are expressed as fold
change with respect to the control unstimulated cells to which value = 1
was assigned. Results are expressed as mean values from three
independent experiments.
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